Extracellular H3.3 Histone Detection and DNase I Degradation for COPD

The patent uses DNase I as an intermediary enzyme that specifically degrades extracellular histone proteins. The enzyme acts as a mediator between the harmful histones and the lung tissue, converting the harmful effect into a beneficial one by selectively removing the toxic extracellular histones while preserving their intracellular anti-microbial function. This resolves the contradiction by introducing a third agent that eliminates the harmful aspect without compromising the protective aspect.

The patent extracts and removes the harmful extracellular histone proteins from the system using DNase I degradation. By taking out the toxic extracellular component separately from the functional intracellular component, the solution eliminates the harmful effect while preserving the beneficial anti-microbial activity. This extraction approach resolves the contradiction by separating the harmful and beneficial aspects of histone presence.

The patent changes the therapeutic parameter from conventional antibiotics to histone-based anti-microbial mechanisms. By utilizing the endogenous anti-microbial properties of histone proteins and enhancing them through controlled extracellular presence (followed by DNase I cleanup), the treatment achieves effectiveness against pathogens that may be resistant to conventional antibiotics while maintaining relative treatment simplicity.

The patent leverages the body's own histone proteins as the anti-microbial agents rather than introducing external antibiotics. The endogenous histones perform the anti-microbial function, and DNase I is used to clean up the resulting extracellular histones. This self-service approach uses the body's existing resources to fight infection, potentially overcoming antibiotic resistance while keeping the treatment protocol simple.

The patent introduces DNase I as an intermediary that specifically targets and degrades extracellular histone proteins. This allows the system to maintain reduced HDAC expression and increased histone acetylation for proper inflammatory regulation, while simultaneously using DNase I to remove the toxic extracellular histones that would otherwise accumulate. The intermediary enzyme resolves the contradiction by enabling one process while mitigating its harmful side effect.

The patent converts the harmful extracellular histone accumulation into a beneficial situation by using DNase I to degrade these histones into harmless peptides and amino acids. The reduced HDAC expression and increased acetylation that would normally lead to toxic extracellular histones are instead managed productively, where the extracellular histones become the target for controlled degradation rather than sources of toxicity.